Optiscan has been featured in the Sydney Morning Herald, The Age, Brisbane Times and Bulls N' Bears regarding its partnership with the University of Minnesota to advance cancer detection in pets. The collaboration focuses on using Optiscan's unique confocal laser endomicroscopy technology to diagnose and treat cancer in companion animals, particularly in cats and dogs.

The research deal formalizes an earlier memorandum of understanding and aims to develop clinical data to support full FDA approval for veterinary use. The technology enables non-invasive, real-time imaging of cancerous cells, which can significantly improve diagnostic accuracy without the need for biopsies.

This partnership comes at a time when over 12 million pets in the U.S. are diagnosed with cancer annually, with breast and oral cancers being the most prevalent. Optiscan's CEO, Dr. Camile Farah, highlighted the significance of this milestone, stating, “This agreement marks another key step in demonstrating that Optiscan's technology can benefit both human and animal healthcare, particularly in veterinary oncology.”

Sydney Morning Herald - Read the full article here.

The Age - Read the full article here. 

Brisbane Times - Read the full article here.